A randomized trial of factor VIII and neutralizing antibodies in hemophilia A

F. Peyvandi, P. M. Mannucci, I. Garagiola, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M. V. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D. M. Nayak, E. Santagostino, M. E. Mancuso, A. C. Sandoval Gonzalez, J. N. Mahlangu & 27 others S. Bonanad Boix, M. Cerqueira, N. P. Ewing, C. Male, T. Owaidah, Soto V. Arellano, N. L. Kobrinsky, S. Majumdar, R. Perez Garrido, A. Sachdeva, M. Simpson, M. Thomas, E. Zanon, B. Antmen, K. Kavakli, M. J. Manco-Johnson, M. Martinez, E. Marzouka, M. G. Mazzucconi, D. Neme, A. Palomo Bravo, R. Paredes Aguilera, A. Prezotti, K. Schmitt, B. M. Wicklund, B. Zulfikar, F. R. Rosendaal

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age

Original languageEnglish
Pages (from-to)2054-2064
Number of pages11
JournalNew England Journal of Medicine
Volume374
Issue number21
DOIs
Publication statusPublished - May 26 2016

Fingerprint

Factor VIII
Hemophilia A
Neutralizing Antibodies
Isoantibodies
Incidence
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. / Peyvandi, F.; Mannucci, P. M.; Garagiola, I.; El-Beshlawy, A.; Elalfy, M.; Ramanan, V.; Eshghi, P.; Hanagavadi, S.; Varadarajan, R.; Karimi, M.; Manglani, M. V.; Ross, C.; Young, G.; Seth, T.; Apte, S.; Nayak, D. M.; Santagostino, E.; Mancuso, M. E.; Sandoval Gonzalez, A. C.; Mahlangu, J. N.; Bonanad Boix, S.; Cerqueira, M.; Ewing, N. P.; Male, C.; Owaidah, T.; Arellano, Soto V.; Kobrinsky, N. L.; Majumdar, S.; Perez Garrido, R.; Sachdeva, A.; Simpson, M.; Thomas, M.; Zanon, E.; Antmen, B.; Kavakli, K.; Manco-Johnson, M. J.; Martinez, M.; Marzouka, E.; Mazzucconi, M. G.; Neme, D.; Palomo Bravo, A.; Paredes Aguilera, R.; Prezotti, A.; Schmitt, K.; Wicklund, B. M.; Zulfikar, B.; Rosendaal, F. R.

In: New England Journal of Medicine, Vol. 374, No. 21, 26.05.2016, p. 2054-2064.

Research output: Contribution to journalArticle

Peyvandi, F, Mannucci, PM, Garagiola, I, El-Beshlawy, A, Elalfy, M, Ramanan, V, Eshghi, P, Hanagavadi, S, Varadarajan, R, Karimi, M, Manglani, MV, Ross, C, Young, G, Seth, T, Apte, S, Nayak, DM, Santagostino, E, Mancuso, ME, Sandoval Gonzalez, AC, Mahlangu, JN, Bonanad Boix, S, Cerqueira, M, Ewing, NP, Male, C, Owaidah, T, Arellano, SV, Kobrinsky, NL, Majumdar, S, Perez Garrido, R, Sachdeva, A, Simpson, M, Thomas, M, Zanon, E, Antmen, B, Kavakli, K, Manco-Johnson, MJ, Martinez, M, Marzouka, E, Mazzucconi, MG, Neme, D, Palomo Bravo, A, Paredes Aguilera, R, Prezotti, A, Schmitt, K, Wicklund, BM, Zulfikar, B & Rosendaal, FR 2016, 'A randomized trial of factor VIII and neutralizing antibodies in hemophilia A', New England Journal of Medicine, vol. 374, no. 21, pp. 2054-2064. https://doi.org/10.1056/NEJMoa1516437
Peyvandi, F. ; Mannucci, P. M. ; Garagiola, I. ; El-Beshlawy, A. ; Elalfy, M. ; Ramanan, V. ; Eshghi, P. ; Hanagavadi, S. ; Varadarajan, R. ; Karimi, M. ; Manglani, M. V. ; Ross, C. ; Young, G. ; Seth, T. ; Apte, S. ; Nayak, D. M. ; Santagostino, E. ; Mancuso, M. E. ; Sandoval Gonzalez, A. C. ; Mahlangu, J. N. ; Bonanad Boix, S. ; Cerqueira, M. ; Ewing, N. P. ; Male, C. ; Owaidah, T. ; Arellano, Soto V. ; Kobrinsky, N. L. ; Majumdar, S. ; Perez Garrido, R. ; Sachdeva, A. ; Simpson, M. ; Thomas, M. ; Zanon, E. ; Antmen, B. ; Kavakli, K. ; Manco-Johnson, M. J. ; Martinez, M. ; Marzouka, E. ; Mazzucconi, M. G. ; Neme, D. ; Palomo Bravo, A. ; Paredes Aguilera, R. ; Prezotti, A. ; Schmitt, K. ; Wicklund, B. M. ; Zulfikar, B. ; Rosendaal, F. R. / A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. In: New England Journal of Medicine. 2016 ; Vol. 374, No. 21. pp. 2054-2064.
@article{d9b8c348f0224709a2f86380882ca987,
title = "A randomized trial of factor VIII and neutralizing antibodies in hemophilia A",
abstract = "BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age",
author = "F. Peyvandi and Mannucci, {P. M.} and I. Garagiola and A. El-Beshlawy and M. Elalfy and V. Ramanan and P. Eshghi and S. Hanagavadi and R. Varadarajan and M. Karimi and Manglani, {M. V.} and C. Ross and G. Young and T. Seth and S. Apte and Nayak, {D. M.} and E. Santagostino and Mancuso, {M. E.} and {Sandoval Gonzalez}, {A. C.} and Mahlangu, {J. N.} and {Bonanad Boix}, S. and M. Cerqueira and Ewing, {N. P.} and C. Male and T. Owaidah and Arellano, {Soto V.} and Kobrinsky, {N. L.} and S. Majumdar and {Perez Garrido}, R. and A. Sachdeva and M. Simpson and M. Thomas and E. Zanon and B. Antmen and K. Kavakli and Manco-Johnson, {M. J.} and M. Martinez and E. Marzouka and Mazzucconi, {M. G.} and D. Neme and {Palomo Bravo}, A. and {Paredes Aguilera}, R. and A. Prezotti and K. Schmitt and Wicklund, {B. M.} and B. Zulfikar and Rosendaal, {F. R.}",
year = "2016",
month = "5",
day = "26",
doi = "10.1056/NEJMoa1516437",
language = "English",
volume = "374",
pages = "2054--2064",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "21",

}

TY - JOUR

T1 - A randomized trial of factor VIII and neutralizing antibodies in hemophilia A

AU - Peyvandi, F.

AU - Mannucci, P. M.

AU - Garagiola, I.

AU - El-Beshlawy, A.

AU - Elalfy, M.

AU - Ramanan, V.

AU - Eshghi, P.

AU - Hanagavadi, S.

AU - Varadarajan, R.

AU - Karimi, M.

AU - Manglani, M. V.

AU - Ross, C.

AU - Young, G.

AU - Seth, T.

AU - Apte, S.

AU - Nayak, D. M.

AU - Santagostino, E.

AU - Mancuso, M. E.

AU - Sandoval Gonzalez, A. C.

AU - Mahlangu, J. N.

AU - Bonanad Boix, S.

AU - Cerqueira, M.

AU - Ewing, N. P.

AU - Male, C.

AU - Owaidah, T.

AU - Arellano, Soto V.

AU - Kobrinsky, N. L.

AU - Majumdar, S.

AU - Perez Garrido, R.

AU - Sachdeva, A.

AU - Simpson, M.

AU - Thomas, M.

AU - Zanon, E.

AU - Antmen, B.

AU - Kavakli, K.

AU - Manco-Johnson, M. J.

AU - Martinez, M.

AU - Marzouka, E.

AU - Mazzucconi, M. G.

AU - Neme, D.

AU - Palomo Bravo, A.

AU - Paredes Aguilera, R.

AU - Prezotti, A.

AU - Schmitt, K.

AU - Wicklund, B. M.

AU - Zulfikar, B.

AU - Rosendaal, F. R.

PY - 2016/5/26

Y1 - 2016/5/26

N2 - BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age

AB - BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age

UR - http://www.scopus.com/inward/record.url?scp=84971222569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971222569&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1516437

DO - 10.1056/NEJMoa1516437

M3 - Article

VL - 374

SP - 2054

EP - 2064

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 21

ER -